Stage‐Specific Health Status in Multiple System Atrophy: EQ ‐ 5D Findings from a European Cohort
Movement Disorders · 06.11.2026
DOI: 10.1002/mds.70593 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 06.11.2026. Verfasst von Igor Kuchin und 23 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Healt…. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Science Fund.
Abstract (Originalsprache)
Background
Multiple system atrophy (MSA) is a rare neurodegenerative disorder that severely impairs health‐related quality of life (HRQoL). Disease progression is assessed using the Unified Multiple System Atrophy Rating Scale Part IV (UMSARS IV), which defines five stages. However, stage‐specific HRQoL estimates, particularly health‐utility values, are unavailable. These estimates are essential for health‐economic evaluation of treatments and for supporting HRQoL as a clinical trial endpoint. Bayesian methods offer a practical approach for analyzing HRQoL in rare diseases.
Objective
To estimate EQ‐5D‐based health‐utility values across UMSARS IV stages in MSA.
Methods
EQ‐5D data from the European MSA Study Group cohort were analyzed. EQ‐5D‐3L responses were mapped to EQ‐5D‐5L health‐utility values using the German value set, where a value of 1 represents perfect health and lower or negative values indicate worse health. Bayesian modeling estimated stage‐specific health‐utility values, reporting posterior means and 95% credible intervals (CrI). Sensitivity analyses included alternative model specifications and imputations of missing UMSARS IV stages.
Results
Stage‐specific EQ‐5D‐5L health‐utility values were 0.672 (95% CrI 0.628–0.719) for UMSARS IV Stage 1, 0.606 (95% CrI 0.523–0.679) for Stage 2, 0.517 (95% CrI 0.416–0.615) for Stage 3, 0.262 (95% CrI 0.158–0.364) for Stage 4, and 0.084 (95% CrI −0.045 to 0.217) for Stage 5. Bayesian models demonstrated good fit, capturing variability within stages and across countries. Sensitivity analyses confirmed robustness, with health‐utility values reflecting expected MSA progression.
Conclusions
This study is the first to provide stage‐specific health‐utility values across all UMSARS IV stages, enabling health‐economic evaluations of emerging interventions and supporting HRQoL as a clinical trial endpoint. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT TIROL - University for Health Sciences a…
- EPICENTER - Institute of Clinical Epidemiology, Public Health, Health Economics, Medical Statistics and Informatics, Medical University of Innsbruck, Innsbruck, Austria.
- Department of Clinical and Movement Neurosciences, University College London, London, UK.
- Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
- Department of Neurology, Medical University of Graz, Graz, Austria.
- Institute for Palliative Care, Paracelsus Medical University, Salzburg, Austria.
ORCID-Profile: Igor Kuchin, Sibylle Puntscher, Gaby Sroczynski, Marjan Arvandi, Julia Santamaria Navarro, Georg Goebel, Anette Schrag, Fabian Leys, Bianca Caliò, Frank Jagusch, Maria Schneller, Klaus Seppi, Stefan Lorenzl, Stefan Kiechl, Richard Dodel, Werner Poewe, Florian Krismer, Petra Schwingenschuh, Alessandra Fanciulli, Uwe Siebert, Beate Jahn
Förderung
- Austrian Science Fund
Zitieren
APA
Kuchin, I., Puntscher, S., Sroczynski, G., Arvandi, M., Santamaria Navarro, J., Goebel, G., Schrag, A., Leys, F., Caliò, B., Jagusch, F., Ndayisaba, J. P., Schneller, M., Seppi, K., Lorenzl, S., Kiechl, S., Dodel, R., Poewe, W., Krismer, F., Schwingenschuh, P., …, & Medical Decision Making in Multiple System Atrophy Research Group Investigators (2026). Stage‐Specific Health Status in Multiple System Atrophy: EQ ‐ 5D Findings from a European Cohort. Movement Disorders. https://doi.org/10.1002/mds.70593
Vancouver
Kuchin I, Puntscher S, Sroczynski G, Arvandi M, Santamaria Navarro J, Goebel G, et al. Stage‐Specific Health Status in Multiple System Atrophy: EQ ‐ 5D Findings from a European Cohort. Movement Disorders. 2026. doi:10.1002/mds.70593
BibTeX
@article{Kuchin2026,
author = {Kuchin, Igor and Puntscher, Sibylle and Sroczynski, Gaby and Arvandi, Marjan and Santamaria Navarro, Julia and Goebel, Georg and Schrag, Anette and Leys, Fabian and Caliò, Bianca and Jagusch, Frank and Ndayisaba, Jean-Pierre and Schneller, Maria and Seppi, Klaus and Lorenzl, Stefan and Kiechl, Stefan and Dodel, Richard and Poewe, Werner and Krismer, Florian and Schwingenschuh, Petra and Fanciulli, Alessandra and Siebert, Uwe and Jahn, Beate and European Multiple System Atrophy Study Group Natural History Study Investigators, European Multiple System Atrophy Study Group Natural History Study Investigators and Medical Decision Making in Multiple System Atrophy Research Group Investigators, Medical Decision Making in Multiple System Atrophy Research Group Investigators},
title = {Stage‐Specific Health Status in Multiple System Atrophy: EQ ‐ 5D Findings from a European Cohort},
journal = {Movement Disorders},
year = {2026},
doi = {10.1002/mds.70593}
}
EUVIMED